JP2019142911A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019142911A5 JP2019142911A5 JP2019076111A JP2019076111A JP2019142911A5 JP 2019142911 A5 JP2019142911 A5 JP 2019142911A5 JP 2019076111 A JP2019076111 A JP 2019076111A JP 2019076111 A JP2019076111 A JP 2019076111A JP 2019142911 A5 JP2019142911 A5 JP 2019142911A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- composition
- composition according
- compound
- cancer vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 7
- 229940022399 cancer vaccine Drugs 0.000 claims 5
- 238000009566 cancer vaccine Methods 0.000 claims 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 3
- -1 phosphorothioate diester Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 2
- 150000004713 phosphodiesters Chemical class 0.000 claims 2
- MFEFTTYGMZOIKO-UHFFFAOYSA-N 5-azacytosine Chemical group NC1=NC=NC(=O)N1 MFEFTTYGMZOIKO-UHFFFAOYSA-N 0.000 claims 1
- 108010044267 Abnormal Hemoglobins Proteins 0.000 claims 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 claims 1
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 claims 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 1
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 claims 1
- 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 claims 1
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 claims 1
- 101000972276 Homo sapiens Mucin-5B Proteins 0.000 claims 1
- 101000874141 Homo sapiens Probable ATP-dependent RNA helicase DDX43 Proteins 0.000 claims 1
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000814512 Homo sapiens X antigen family member 1 Proteins 0.000 claims 1
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 claims 1
- 102100027252 Melanoma-associated antigen C2 Human genes 0.000 claims 1
- 102100034263 Mucin-2 Human genes 0.000 claims 1
- 102100022494 Mucin-5B Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000036673 PRAME Human genes 0.000 claims 1
- 108060006580 PRAME Proteins 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 102100035724 Probable ATP-dependent RNA helicase DDX43 Human genes 0.000 claims 1
- 102100037686 Protein SSX2 Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 102100039490 X antigen family member 1 Human genes 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000005690 diesters Chemical class 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004437 phosphorous atom Chemical group 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 0 *C1[C@](N(C=NC(N)=N2)C2=O)O[C@](CO)C1OP(*)(OC[C@](C(C1*=C)N)O[C@@]1[n]1c(N=C(*)NC2=O)c2nc1)=O Chemical compound *C1[C@](N(C=NC(N)=N2)C2=O)O[C@](CO)C1OP(*)(OC[C@](C(C1*=C)N)O[C@@]1[n]1c(N=C(*)NC2=O)c2nc1)=O 0.000 description 4
- HVHZDGNAWQEZRD-LFYCGXNYSA-N COC1[C@H](N(C=[N+](C(N)=N2)[O-]C3[C@H]([n]4c(N=C(N)NC5=O)c5nc4)O[C@H](CO)C3OP(O)(OC3)=O)C2=O)O[C@H]3C1O Chemical compound COC1[C@H](N(C=[N+](C(N)=N2)[O-]C3[C@H]([n]4c(N=C(N)NC5=O)c5nc4)O[C@H](CO)C3OP(O)(OC3)=O)C2=O)O[C@H]3C1O HVHZDGNAWQEZRD-LFYCGXNYSA-N 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361771525P | 2013-03-01 | 2013-03-01 | |
| US61/771,525 | 2013-03-01 | ||
| US201361887165P | 2013-10-04 | 2013-10-04 | |
| US61/887,165 | 2013-10-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560330A Division JP6514647B2 (ja) | 2013-03-01 | 2014-02-27 | 薬物組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019142911A JP2019142911A (ja) | 2019-08-29 |
| JP2019142911A5 true JP2019142911A5 (https=) | 2019-12-26 |
Family
ID=50288308
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560330A Expired - Fee Related JP6514647B2 (ja) | 2013-03-01 | 2014-02-27 | 薬物組み合わせ |
| JP2019076111A Pending JP2019142911A (ja) | 2013-03-01 | 2019-04-12 | 薬物組み合わせ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560330A Expired - Fee Related JP6514647B2 (ja) | 2013-03-01 | 2014-02-27 | 薬物組み合わせ |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20160015805A1 (https=) |
| EP (2) | EP3563836A1 (https=) |
| JP (2) | JP6514647B2 (https=) |
| KR (1) | KR20150125963A (https=) |
| CN (2) | CN110448566A (https=) |
| AU (1) | AU2014223348B2 (https=) |
| CA (1) | CA2902433A1 (https=) |
| CY (1) | CY1122554T1 (https=) |
| DK (1) | DK2961388T3 (https=) |
| ES (1) | ES2734023T3 (https=) |
| HR (1) | HRP20191171T1 (https=) |
| HU (1) | HUE044430T2 (https=) |
| IL (2) | IL240894B (https=) |
| LT (1) | LT2961388T (https=) |
| MX (2) | MX366967B (https=) |
| PH (2) | PH12015501905A1 (https=) |
| PL (1) | PL2961388T3 (https=) |
| PT (1) | PT2961388T (https=) |
| RU (2) | RU2019138702A (https=) |
| SA (1) | SA515360959B1 (https=) |
| SG (2) | SG11201506727RA (https=) |
| SI (1) | SI2961388T1 (https=) |
| WO (1) | WO2014134355A1 (https=) |
| ZA (2) | ZA201506150B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| EP2750768B1 (en) | 2011-08-30 | 2018-10-03 | Astex Pharmaceuticals, Inc. | Decitabine derivative formulations |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| AU2015228372B2 (en) | 2014-03-12 | 2018-05-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| PT3142751T (pt) * | 2014-05-13 | 2019-10-25 | Medimmune Ltd | Anticorpos anti-b7-h1 e anti-ctla-4 para o tratamento de cancro de pulmão de não pequenas células. |
| US10869926B2 (en) | 2014-07-15 | 2020-12-22 | The Johns Hopkins University | Suppression of myeloid derived suppressor cells and immune checkpoint blockade |
| RU2684911C2 (ru) | 2014-10-07 | 2019-04-16 | Ситлимик Инк. | Пептид, полученный из hsp70, фармацевтическая композиция для лечения или профилактики рака, содержащая такой пептид, индуктор иммунного ответа и способ получения антиген-презентирующей клетки |
| WO2016061231A1 (en) * | 2014-10-14 | 2016-04-21 | Deciphera Pharmaceuticals, Llc | Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression |
| US10525035B2 (en) * | 2014-12-18 | 2020-01-07 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of retinopathy and other ocular diseases |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| CN107428815B (zh) | 2015-03-09 | 2021-07-09 | Cytlimic公司 | 源于gpc3的肽、使用其的用于治疗或预防癌症的医药组合物、免疫诱导剂、及抗原呈递细胞的制造方法 |
| AU2016244570B2 (en) * | 2015-04-07 | 2020-08-27 | Nec Corporation | Medicine |
| AU2016287585B2 (en) * | 2015-07-02 | 2020-12-17 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
| AU2017342189B2 (en) | 2016-10-11 | 2023-09-21 | Nec Corporation | Medicine |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704966D0 (en) * | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| KR20200035438A (ko) | 2017-08-03 | 2020-04-03 | 오쓰까 세이야꾸 가부시키가이샤 | 약물 화합물 및 이의 정제 방법 |
| US20210002371A1 (en) * | 2017-12-21 | 2021-01-07 | Brian A. Sherer | Combination of an anti-pd-l1 antibody and ido1 inhibitor for the treatment of cancer |
| CN108948203B (zh) * | 2018-08-09 | 2019-06-04 | 南京鼓楼医院 | 抗pd-1单克隆抗体及其制备方法和应用 |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| PH12022552820A1 (en) * | 2020-04-24 | 2024-03-25 | Genexine Inc | Method for treating cervical cancer |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
| PT1053325E (pt) | 1998-02-05 | 2006-05-31 | Glaxosmithkline Biolog Sa | Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao. |
| DK1141028T3 (da) | 1998-12-23 | 2010-05-25 | Pfizer | Humane monoklonale antistoffer til CTLA-4 |
| GB9908885D0 (en) * | 1999-04-19 | 1999-06-16 | Smithkline Beecham Biolog | Vccine |
| DE60014076T2 (de) * | 1999-04-19 | 2005-10-13 | Glaxosmithkline Biologicals S.A. | Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| US20030148973A1 (en) | 2001-05-23 | 2003-08-07 | Peter Emtage | MAGE-A1 peptides for treating or preventing cancer |
| EP1551225A4 (en) * | 2002-06-10 | 2011-05-25 | Avax Technologies Inc | KRYOKONSERVATION OF HAPEN-MODIFIED TUMOR CELLS |
| WO2005033278A2 (en) | 2003-09-30 | 2005-04-14 | Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus iscom |
| ATE422367T1 (de) * | 2004-05-26 | 2009-02-15 | Biovaxim Ltd | Zusammensetzungen aus demethylierenden mitteln als verstärker der immuntherapie zur behanldung von chronischen infektionen und neoplastischen erkrankungen und behandlungsverfahren dafür |
| RU2007114111A (ru) | 2004-11-04 | 2008-12-10 | Пфайзер Продактс Инк. (Us) | Лечение рака молочной железы с помощью комбинации антитела против ctla4 и ингибитора ароматазы |
| AU2005321898B2 (en) | 2004-12-29 | 2012-07-19 | Mannkind Corporation | Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines |
| AU2006204896A1 (en) * | 2005-01-14 | 2006-07-20 | Avax Technologies, Inc. | Method for producing a vaccine for the treatment of cancer |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| SI1928492T1 (sl) * | 2005-09-01 | 2011-09-30 | Celgene Corp | Imunoloĺ ka uporaba imunomodulatornih spojin za cepivo in protiinfekcijsko bolezensko terapijo |
| US7700567B2 (en) * | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| CA2767253A1 (en) * | 2009-07-06 | 2011-01-13 | Ontorii, Inc. | Novel nucleic acid prodrugs and methods of use thereof |
| SMT201700293T1 (it) * | 2009-07-20 | 2017-07-18 | Bristol Myers Squibb Co | Combinazione di un anticorpo anti-ctla-4 con etoposide per il trattamento sinergico di malattie proliferative |
| CN102781965A (zh) * | 2009-10-06 | 2012-11-14 | 安吉奥开米公司 | 用于转运治疗剂的组合物和方法 |
| GB201006096D0 (en) * | 2010-04-13 | 2010-05-26 | Alligator Bioscience Ab | Novel compositions and uses thereof |
| CA2810668A1 (en) | 2010-09-08 | 2012-03-15 | Halozyme, Inc. | Methods for assessing and identifying or evolving conditionally active therapeutic proteins |
| BR112013026199A2 (pt) * | 2011-04-15 | 2017-11-07 | Compugen Ltd | polipeptídeo isolado, proteína de fusão, sequência de ácidos nucleicos, vetor de expressão ou um vírus, célula recombinante, método de produção de um polipeptídeo com ectodomínio solúvel lsr, ou seu fragmento ou proteína de fusão, composição farmacêutica, uso de um anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, uso do anticorpo ou do fragmento de ligação ao antígeno, uso de qualquer um de um polipeptídeo isolado, método de regulação por cima de citocinas, indução da expansão de células t, promoção da imunidade de células t específica antigênica e promoção da ativação das células t cd4+ e/ou cd8+ em um sujeito, método para potenciação de uma resposta imune secundária a um antígeno em um paciente, método de uso de pelo menos um de: um polipeptídeo isolado, método para tratamento ou prevenção de uma condição relacionada com o sistema imune, método para tratamento ou prevenção de uma doença infecciosa, método para diagnóstico de uma doença em um sujeito, método de produção de um polipeptídeo com ectodomínio solúvel tmem25, vsig10, ly6g6f, ou seu fragmento ou proteína de fusão, anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, método de imunoterapia em um paciente e método para combinação de vacinação terapêutica com um antígeno em conjunto com a administração de qualquer um de um polipeptídeo |
| EP2750768B1 (en) * | 2011-08-30 | 2018-10-03 | Astex Pharmaceuticals, Inc. | Decitabine derivative formulations |
| EP2958571B1 (en) * | 2013-02-21 | 2024-04-10 | Michele Maio | Dna hypomethylating agents for cancer therapy |
-
2014
- 2014-02-27 SI SI201431263T patent/SI2961388T1/sl unknown
- 2014-02-27 LT LTEP14710728.8T patent/LT2961388T/lt unknown
- 2014-02-27 HR HRP20191171TT patent/HRP20191171T1/hr unknown
- 2014-02-27 RU RU2019138702A patent/RU2019138702A/ru unknown
- 2014-02-27 PL PL14710728T patent/PL2961388T3/pl unknown
- 2014-02-27 US US14/771,011 patent/US20160015805A1/en not_active Abandoned
- 2014-02-27 RU RU2015141628A patent/RU2708246C2/ru active
- 2014-02-27 EP EP19163282.7A patent/EP3563836A1/en not_active Withdrawn
- 2014-02-27 CN CN201910760009.5A patent/CN110448566A/zh active Pending
- 2014-02-27 CN CN201480011754.5A patent/CN105025884B/zh not_active Expired - Fee Related
- 2014-02-27 PT PT14710728T patent/PT2961388T/pt unknown
- 2014-02-27 DK DK14710728.8T patent/DK2961388T3/da active
- 2014-02-27 SG SG11201506727RA patent/SG11201506727RA/en unknown
- 2014-02-27 JP JP2015560330A patent/JP6514647B2/ja not_active Expired - Fee Related
- 2014-02-27 KR KR1020157025503A patent/KR20150125963A/ko not_active Ceased
- 2014-02-27 MX MX2015011147A patent/MX366967B/es active IP Right Grant
- 2014-02-27 HU HUE14710728 patent/HUE044430T2/hu unknown
- 2014-02-27 AU AU2014223348A patent/AU2014223348B2/en not_active Ceased
- 2014-02-27 ES ES14710728T patent/ES2734023T3/es active Active
- 2014-02-27 WO PCT/US2014/019137 patent/WO2014134355A1/en not_active Ceased
- 2014-02-27 CA CA2902433A patent/CA2902433A1/en not_active Abandoned
- 2014-02-27 SG SG10201707135RA patent/SG10201707135RA/en unknown
- 2014-02-27 EP EP14710728.8A patent/EP2961388B1/en active Active
-
2015
- 2015-08-24 ZA ZA201506150A patent/ZA201506150B/en unknown
- 2015-08-27 IL IL240894A patent/IL240894B/en active IP Right Grant
- 2015-08-27 MX MX2019008822A patent/MX2019008822A/es unknown
- 2015-08-28 PH PH12015501905A patent/PH12015501905A1/en unknown
- 2015-08-30 SA SA515360959A patent/SA515360959B1/ar unknown
-
2019
- 2019-04-12 JP JP2019076111A patent/JP2019142911A/ja active Pending
- 2019-07-10 CY CY20191100738T patent/CY1122554T1/el unknown
- 2019-07-17 US US16/514,377 patent/US20200009247A1/en not_active Abandoned
- 2019-08-16 ZA ZA2019/05426A patent/ZA201905426B/en unknown
- 2019-10-17 PH PH12019550222A patent/PH12019550222A1/en unknown
-
2020
- 2020-09-15 IL IL277385A patent/IL277385A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019142911A5 (https=) | ||
| RU2019138702A (ru) | Комбинации лекарственных средств | |
| KR102057751B1 (ko) | 테노포비르 전구약물 및 그의 약학적 용도 | |
| JP2019522055A5 (https=) | ||
| JP2013518116A5 (https=) | ||
| JP2015508103A5 (https=) | ||
| ES2703257T3 (es) | Compuestos y composiciones para el tratamiento del cáncer | |
| JP2017508789A5 (https=) | ||
| JP2009541236A5 (https=) | ||
| JP2016510030A5 (https=) | ||
| RU2012136468A (ru) | Производные фуро[3,2,-в]пирана, применимые в синтезе аналогов | |
| JP2005504749A5 (https=) | ||
| JP2005502635A5 (https=) | ||
| JP2016526540A5 (https=) | ||
| JP2002514161A (ja) | ガンおよび他の細胞増殖性疾患の治療に有用なレチノイルオキシ（置換）アルキレンブチレート | |
| JP2016515128A5 (https=) | ||
| JP2008510778A5 (https=) | ||
| CY1108498T1 (el) | Συνθεση εμβολιου η οποια περιεχει ως εκδοχο μια αλκυλφωσφατιδυλοχολινη | |
| JP2013536227A5 (https=) | ||
| JP2016536360A5 (https=) | ||
| JP2009167162A5 (https=) | ||
| JP2022533020A (ja) | がん免疫療法アジュバント | |
| JP2010531855A5 (https=) | ||
| JP2011513471A5 (https=) | ||
| RU2018104555A (ru) | Новое соединение, специфически связывающееся с рецептором ampa |